• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ACS Omega . Rapid Identification of H3N2 Influenza A Virus HA-Targeting Antibody Epitopes Driven by Computational Antibody Similarity Measures

tetano

Editor, Senior Moderator
ACS Omega

. 2026 Oct 15;11(42):64613-64623.
doi: 10.1021/acsomega.6c04366. eCollection 2026 Oct 27.

Rapid Identification of H3N2 Influenza A Virus HA-Targeting Antibody Epitopes Driven by Computational Antibody Similarity Measures​


Zheng Zhu 1 2 , Zhengshan Chen 1 , Jinxia Wu 1 , Jin Han 1 , Linkuo Li 1 , Kewen Qian 1 , Yue Cui 1 , Zeya Li 1 , Rongjun Ding 1 , Shixin Pang 1 , Guanying Zhang 1 , Changming Yu 1 , Xiangyang Chi 1

Affiliations Expand


Abstract​


Antibodies are important therapeutic agents for the prevention and treatment of influenza, and hemagglutinin (HA) serves as the primary target for the development of therapeutic antibodies. However, the identification of epitopes remains an unmet need in the development of such therapeutic antibodies. This study investigates the characteristics of antibody-HA binding interfaces (i.e., epitopes and paratopes) through a computational analysis of all antibody-HA complexes with nonredundant experimentally determined structures from SAbDab, the largest reported antibody structure data set to date. After experimentally identifying and selecting H3N2 HA-specific binding antibodies, a reference antibody library was established. For anti-H3N2 HA antibodies with unknown structures, epitope grouping was conducted based on competitive binding assays that assess interference with the binding of antibodies from the reference library. Based on the complementary relationship between epitope and paratope structures, we selected the structure-based similarity measure most relevant to epitope convergence. Furthermore, we prioritized the experimental validation of binding interference between candidate antibodies and their most structurally similar reference antibodies. We present an integrated computational and experimental framework. This approach includes the construction of an H3N2-specific reference antibody set, computational modeling of antibodies, measurement of antibody similarity, and is complemented by antibody competition binding assays. The dry-wet iterative protocol presented here yielded accurate assessment of the neutralizing potency and breadth of the previously uncharacterized antibody P2A10. Together, the presented pipeline offers a powerful approach for identifying epitopes on anti-H3N2 HA antibodies and for epitope-targeted antibody discovery, while demonstrating the effectiveness of structural analytics in reducing experimental labor.
 
Back
Top Bottom